Electric Power Research Institute Incorporated

C4 Therapeutics, Inc.

Dana-farber-cancer Institute Inc.

University of Colorado

Andrew John Phillips

James A Henderson

Christopher G Nasveschuk

Yanke Liang

Minsheng He

J Mark Major

Kiel Lazarski

Robert Carlton Lynch

Ryan E Michael

Martin Duplessis

Dennis Buckley

Georg Winter

Glynn R Bartlett

Timothy P Heffernan

Chi-Li Chen

Mark E Fitzgerald

Justin Roberts

Behnam Nabet

Mark Major

Chris G Nasveschuk

Christiaan Engelbrecht

James Elliott Bradner

Gesine Kerstin Veits

J Finely Bush

Gan Zhang

Kristopher Charles Kozak

Xuedong Liu

Dana Ungermannova

Andrew Charles Good

Sam Harrell

Chris Engelbecht

Harit U Vora

Yansheng Liu

Christiaan S Engelbecht

James Bradner

Sike Xia

Katrina L Jackson

Tiebin Zhao

Cody Michael Porter

Jerry A Towler

Shridas Ningileri

Andrew H Stewart

Steven Wallace Eckroad

Lester Ray Harrell

Gary Charles Sibilant

Daniel Clinton Lawry

Drew Benton McGuire

Timothy Scott Shaw

Mark C Webb

Kyle Hill

Brandon Rummage

Bob Lynch

Eric Engdahl

Phillip Nathan Beverly

Jason Cary Nave

Ian Royappan Meinzen

Neil J Hurst

J Finley Bush

Chenghe Xiao

Gordon Luke Van Der Zel

Victoria Garza

Randy Horton

Charles Perry

James Wu

Robert C Lynch

Brandon Rummange

Christiaan Stephen Engelbrecht

Glynn Ray Bartlett

Christiaan Stephan Engelbrecht

This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.

Targeted protein degradation

This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.

N/O-linked degrons and degronimers for protein degradation

This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) ('Degrons'), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

Heterocyclic degronimers for target protein degradation

This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

Spirocyclic degronimers for target protein degradation

This invention provides amine-linked C-glutarimide Degronimers for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation, wherein the C-glutarimide Degronimers have the formula:

Substituted piperidine Degronimers for Target Protein degradation

The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.

Tunable endogenous protein degradation with heterobifunctional compounds

This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

C-carbon linked glutarimide degronimers for target protein degradation

A surge protection apparatus is disclosed. The surge protection apparatus includes a housing; electronics contained in the housing; and a plurality of metal tabs electrically connected to the electronics, the metal tabs being configured to connect to a terminal block of a relay panel in a substation, the metal tabs electrically connecting the terminal block to the electronics to provide EMP surge protection to the relay panel.

Surge protection apparatus and method for substation protective relays

The invention provides cereblon binders of Formulas: or pharmaceutically acceptable salts thereof, for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications to treat medical disorders including, but not limited to cancer.

Cereblon binders for the degradation of ikaros

Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.

Degraders and Degrons for targeted protein degradation

N/O-linked Degrons and Degronimers for protein degradation

Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

Tricyclic degraders of Ikaros and Aiolos

This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

Regulating chimeric antigen receptors

Tunable endogenous protein degradation

Growing community of inventors

Harrisburg, NC, United States of America

Andrew John Phillips